Cardiovascular Disease Prevention: ApoB Protocol

Quick answer: Cardiovascular disease is 80–90% preventable with optimal metabolic health — yet standard preventive cardiology misses the majority of future heart attack patients because LDL cholesterol is a poor predictor of individual risk. ApoB (the count of atherogenic particles — LDL, VLDL, IDL) is the superior predictor: every particle entering the arterial wall carries one ApoB molecule, and particle number — not cholesterol content per particle — determines atherosclerosis progression rate. The evidence-based cardiovascular protection protocol: ApoB below 60 mg/dL (primary prevention target), lipoprotein(a) testing once per lifetime, high-sensitivity CRP below 1.0 mg/L, and the diet-exercise-supplement stack that reduces ApoB and inflammation simultaneously.

Why LDL Cholesterol Is the Wrong Target

The standard lipid panel — total cholesterol, LDL-C, HDL-C, and triglycerides — was designed in the 1960s when cholesterol measurement was the only available technology. The problem with LDL-C as a cardiovascular risk marker is that it measures the cholesterol content of LDL particles, not the number of particles. LDL particle size varies substantially: small, dense LDL particles carry less cholesterol per particle than large, buoyant particles. Two people can have identical LDL-C levels with dramatically different cardiovascular risk — the person with 1,800 small dense particles (high ApoB) has far greater risk than someone with 1,000 large particles at the same LDL-C. This is the “LDL discordance” phenomenon — it affects 20–30% of adults and explains why many heart attacks occur in people with “normal” LDL-C.

ApoB (apolipoprotein B100) is superior because every atherogenic lipoprotein particle — LDL, VLDL, IDL, Lp(a) — carries exactly one ApoB molecule. ApoB directly counts the number of particles capable of entering the arterial wall and initiating the inflammatory cascade that leads to atherosclerotic plaque. The MESA study, PREDIMED, and multiple Mendelian randomization studies confirm ApoB as the superior predictor of MACE (major adverse cardiovascular events) compared to LDL-C. Optimal ApoB for primary prevention is below 60–80 mg/dL; for secondary prevention (existing atherosclerosis or prior MACE) the target is below 50–60 mg/dL. The standard lab reference range for ApoB (below 130 mg/dL) is calibrated for population normality, not cardiovascular disease prevention.

The Cardiovascular Biomarker Panel That Actually Predicts Risk

The optimal cardiovascular risk assessment panel: ApoB (goal below 60 mg/dL for primary prevention — not just “in range” below 130 mg/dL), lipoprotein(a) or Lp(a) (a genetically determined independent cardiovascular risk factor present in 15–20% of people at high levels — should be measured once per lifetime since it is largely fixed by genetics; level above 50 mg/dL or 125 nmol/L represents significant additional risk that standard LDL-lowering does not address), high-sensitivity CRP or hs-CRP (goal below 1.0 mg/L — the JUPITER trial showed that people with elevated hs-CRP but “normal” LDL had 50% reduction in MACE with statin therapy, establishing inflammation as an independent causal factor), fasting insulin and HOMA-IR (insulin resistance is the root cause of the atherogenic lipoprotein pattern — small dense LDL, high VLDL, low HDL — that drives plaque formation), and coronary artery calcium (CAC) score for individuals over 40 with intermediate risk (the most powerful reclassification tool available — a CAC of 0 essentially eliminates near-term MI risk even in people with elevated traditional risk factors; CAC above 400 indicates advanced disease requiring aggressive intervention).

Non-HDL cholesterol (total cholesterol minus HDL) is an intermediate option — better than LDL-C because it captures all atherogenic lipoproteins including VLDL and IDL — when ApoB testing is not available. Non-HDL goal: below 100 mg/dL for primary prevention, below 80 mg/dL for secondary prevention. The triglyceride/HDL ratio is a validated insulin resistance surrogate: below 1.5 is optimal; above 3.0 indicates insulin resistance and the accompanying atherogenic lipoprotein pattern.

Root Causes of Cardiovascular Disease: Beyond Cholesterol

Insulin resistance and the atherogenic lipoprotein pattern: Insulin resistance produces a specific lipoprotein phenotype that is highly atherogenic even when LDL-C is “normal”: elevated VLDL (triglycerides above 150 mg/dL), reduced HDL-C, and a shift from large buoyant LDL to small dense LDL — all driven by hepatic de novo lipogenesis from insulin-resistant liver cells producing excess VLDL. Treating the root cause — reversing insulin resistance via resistance training, TRE, and berberine — typically reduces ApoB 15–30% and triglycerides 30–50% independently of statin therapy, by eliminating the VLDL and IDL overflow that converts to small dense LDL.

Chronic inflammation (inflammaging): Atherosclerosis is fundamentally an inflammatory disease. LDL particles oxidize within the arterial intima, triggering macrophage foam cell formation, endothelial dysfunction, and plaque development. The inflammatory load — driven by visceral fat, gut dysbiosis, sleep deprivation, and advanced glycation end products — determines the rate of plaque initiation and progression. The CANTOS trial demonstrated that targeting inflammation directly (with canakinumab, an IL-1β antibody) reduced MACE by 15% independently of LDL changes — confirming that inflammation is a causal driver of cardiovascular events, not merely a marker. Anti-inflammatory dietary interventions reducing hs-CRP below 1.0 mg/L are mechanistically equivalent.

Endothelial dysfunction: The endothelium — the single-cell lining of blood vessels — controls vascular tone, prevents platelet aggregation, and regulates lipoprotein entry into the arterial wall. Endothelial dysfunction (reduced nitric oxide bioavailability, increased adhesion molecule expression) is the earliest measurable step in atherosclerosis — present decades before clinical events. Insulin resistance, oxidative stress, inflammation, and physical inactivity all impair endothelial function. Zone 2 aerobic exercise is the most potent endothelial function restorer — it increases eNOS (endothelial nitric oxide synthase) expression and shear stress-mediated NO production.

The Cardiovascular Protection Protocol

Diet: The Mediterranean Pattern and Beyond

The PREDIMED trial — the largest RCT of dietary patterns and cardiovascular outcomes — found that a Mediterranean diet supplemented with extra-virgin olive oil or mixed nuts reduced MACE by 30% compared to a low-fat control diet in high-risk individuals. The mechanisms are multiple: EVOO’s oleocanthal and oleuropein reduce NF-κB-mediated inflammation and endothelial adhesion molecule expression; omega-3-rich fish reduces VLDL and atherogenic particle count; the fiber and polyphenol content reduces gut LPS translocation and visceral fat; and the displacement of refined carbohydrates reduces the VLDL overproduction driven by hepatic de novo lipogenesis. Specific dietary targets: eliminate liquid sugar and refined grain (highest-yield intervention for ApoB reduction in insulin-resistant individuals), 4+ weekly servings of fatty fish (or omega-3 EPA+DHA 3–4 g/day), daily EVOO, and legumes over refined starch as the carbohydrate foundation.

Exercise: VO2max as the Target

VO2max is the single strongest predictor of cardiovascular and all-cause mortality. The lowest-fitness quintile has 5x the cardiovascular mortality of the highest-fitness quintile — a risk differential larger than smoking. Zone 2 exercise (150–300 minutes/week) restores endothelial function, reduces visceral fat (the source of atherogenic VLDL and inflammatory cytokines), lowers resting heart rate, and improves the ApoB-lowering lipoprotein response. Resistance training adds an independent 15–20% cardiovascular mortality reduction via different mechanisms — improved insulin sensitivity, reduced visceral adiposity, and maintenance of lean mass that modulates cardiometabolic risk. For people with established coronary artery disease, cardiac rehabilitation programs with supervised aerobic exercise have the strongest evidence base for secondary prevention.

Supplements with Cardiovascular Evidence

Omega-3 fatty acids (EPA+DHA at 4 g/day) reduce triglycerides by 20–30% dose-dependently and reduced MACE by 25% in the REDUCE-IT trial using icosapentaenoic acid (EPA only, as Vascepa). The triglyceride-lowering effect is directly relevant to ApoB reduction — high VLDL triglycerides are a direct source of atherogenic particles. Berberine at 1,500 mg/day reduces ApoB-relevant markers: LDL-C by 20%, triglycerides by 23%, while raising HDL by 3% — through LDLR upregulation and PCSK9 inhibition in addition to its AMPK mechanism. Coenzyme Q10 (CoQ10 as ubiquinol 200–300 mg/day) — the Q-SYMBIO trial found 43% reduction in cardiovascular mortality in heart failure patients; for primary prevention, CoQ10 addresses the mitochondrial dysfunction in cardiac and vascular smooth muscle cells that contributes to heart failure and arterial stiffness. For statin users, CoQ10 supplementation is particularly important because statins inhibit the mevalonate pathway, reducing endogenous CoQ10 synthesis alongside LDL reduction.

When Statins Are Appropriate

Statins have the strongest pharmacological evidence for MACE reduction and are appropriate for: secondary prevention (anyone with established atherosclerosis, prior MI, or stroke), primary prevention with ApoB above 80 mg/dL despite lifestyle optimization (or above 60 mg/dL with additional risk factors), and elevated Lp(a) with other risk factors (though statins do not lower Lp(a) and PCSK9 inhibitors are preferred for Lp(a) reduction). The debate in primary prevention is whether to use statins to compensate for suboptimal lifestyle versus optimizing the root causes that elevate ApoB in the first place. The functional medicine framework prioritizes root cause resolution first — the majority of people with elevated ApoB driven by insulin resistance and dietary refined carbohydrates can normalize ApoB to below 60–70 mg/dL through lifestyle without pharmacological support. Statins remain the appropriate adjunct when lifestyle optimization alone is insufficient.

Cardiovascular disease is not inevitable — it is the cumulative consequence of addressable metabolic dysfunction. The foundation is insulin sensitivity, chronic inflammation control, sleep optimization, and aerobic fitness. Call our office at (810) 206-1402 to schedule a comprehensive cardiovascular risk assessment including ApoB, Lp(a), hs-CRP, CAC scoring guidance, and a personalized prevention protocol.

Frequently Asked Questions

What is ApoB and why does it matter?
ApoB (apolipoprotein B100) is a protein present on every atherogenic lipoprotein particle — one ApoB molecule per LDL, VLDL, IDL, and Lp(a) particle. Unlike LDL cholesterol (which measures the cholesterol content inside LDL particles), ApoB directly counts the number of particles capable of entering the arterial wall and initiating atherosclerosis. Optimal ApoB for cardiovascular disease prevention is below 60-80 mg/dL for primary prevention — not just below the standard lab reference range of 130 mg/dL. The MESA, PREDIMED, and multiple Mendelian randomization studies confirm ApoB as superior to LDL-C for cardiovascular risk prediction, particularly in people with insulin resistance where small dense LDL predominates.

What is the best diet for heart health?
The Mediterranean dietary pattern has the strongest RCT evidence for cardiovascular disease prevention. The PREDIMED trial found 30% reduction in major adverse cardiovascular events (MACE) with Mediterranean diet plus EVOO or nuts compared to low-fat diet. Key components: daily extra-virgin olive oil (oleocanthal reduces inflammation, oleuropein inhibits endothelial NF-kB), 4+ weekly servings of fatty fish or omega-3 supplementation (reduces VLDL triglycerides and atherogenic particle count), legumes as the carbohydrate foundation (low glycemic, high fiber, reduces insulin-driven VLDL production), elimination of liquid sugar and refined grain (the highest-yield dietary change for ApoB reduction in insulin-resistant individuals), and daily nuts (walnuts specifically reduce small dense LDL and ApoB).

What does lipoprotein(a) mean?
Lipoprotein(a) or Lp(a) is a modified LDL particle with an additional apolipoprotein(a) chain attached via a disulfide bond. It is primarily genetically determined — 90% of your Lp(a) level is set by the LPA gene, not by lifestyle. Elevated Lp(a) above 50 mg/dL (or 125 nmol/L) is present in 15-20% of people and represents an independent, additive cardiovascular risk factor that standard LDL-lowering therapies do not address. Lp(a) is particularly atherogenic because it carries oxidized phospholipids and has pro-inflammatory and pro-thrombotic properties beyond standard LDL. Testing should be done once per lifetime since it is largely stable. If elevated, more aggressive ApoB lowering targets, aspirin consideration, and PCSK9 inhibitor therapy (which reduces Lp(a) 20-30%) are appropriate with physician guidance.

Can you reverse atherosclerosis?
Atherosclerotic plaque stabilization and partial regression are achievable with aggressive intervention. IVUS (intravascular ultrasound) studies show measurable plaque regression with intensive statin therapy achieving LDL-C below 70 mg/dL (or ApoB below 60 mg/dL) — particularly over 18-24 months of sustained treatment. The REVERSAL and ASTEROID trials demonstrated plaque regression with high-dose statins. Beyond statins, the CANTOS trial showed plaque stabilization via inflammation reduction. The realistic goal for most people is halting progression and stabilizing vulnerable plaques (fibrous cap thickening that prevents rupture) rather than complete regression — which remains more limited. Prevention while the arterial wall is still healthy is far more effective than reversal once plaque is established.

Cardiovascular Disease Prevention: ApoB, Lp(a), and the Evidence-Based Protocol